We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

17 hedge funds and large institutions have $118K invested in Moleculin Biotech in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 16 → 17 (+1)

7.8% less ownership

Funds ownership: 10.56% → 2.76% (-7.8%)

85% less capital inflows, than outflows

Capital inflows: $190K | Capital outflows: $1.29M

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$67.7K
2
XTX Topco
XTX Topco
Cayman Islands
+$51.3K
3
Virtu Financial
Virtu Financial
New York
+$48.8K
4
LPL Financial
LPL Financial
California
+$8.2K
5
UBS Group
UBS Group
Switzerland
+$6.56K

Top Sellers

Rank Fund Capital Flow
1
Armistice Capital
Armistice Capital
New York
-$1.22M
2
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
-$68.2K
3
Barclays
Barclays
United Kingdom
-$335
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$33

MBRX Hedge Fund Activity: Q2 2025 in Review

17 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2025, worth a combined $118K — down 92% from $1.44M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MBRX positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Citigroup, adding an estimated $67.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.22M sold.

  • 17 institutional investors held Moleculin Biotech (MBRX) as of Q2 2025, up from 16 in Q1 2025.
  • Funds reported $118K of Moleculin Biotech stock for Q2 2025, down 92% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q2 2025 and 3 closed out, a net change of +1 holder.
  • The largest Moleculin Biotech buyer in Q2 2025 was Citigroup, an estimated $67.7K added.
  • The largest Moleculin Biotech seller in Q2 2025 was Armistice Capital, an estimated $1.22M sold.

Based on aggregated 13F filings for Q2 2025.